Sutro Biopharma adds $100M to at-the-market equity program via new shelf registration

SUTRO BIOPHARMA, INC.

Filed prospectus supplement to 2023 Form S-3 shelf, increasing shares available under existing Sales Agreement with Jefferies by $100M.
Total remaining capacity as of Feb 9, 2024: $29.3M from prior shelf plus $100M new supplement = $129.3M.
Previously sold $70.7M under the 2021 shelf registration since April 2021.
Shares sold through Jefferies LLC as sales agent at prevailing market prices.
Legal opinion on share validity filed as Exhibit 5.1 from Fenwick & West.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.